Nutritional therapy of inflammatory bowel disease;Thérapeutique nutritionnelle des maladies inflammatoires chroniques de l'intestin

Nutrition Clinique et Metabolisme

Volumn 16, Issue 3, 2002, Pages 202-205

  Desreumaux, Pierre ^a   Dubuquoy, Laurent ^a   Malamut, Georgia ^a   Cheng, Yang ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Acute colitis; Crohn's disease; PPAR; Probiotics

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

CHRONIC INFLAMMATION; COLITIS; CONFERENCE PAPER; CROHN DISEASE; ENTERITIS; HUMAN; NUTRITION;

EID: 0036763494     PISSN: 09850562     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0985-0562(02)00155-3     Document Type: Conference Paper

References (15)

1. Dickinson RJ, Ashton MG, Axon AT, Smith RC, Yeung CK, Hill GL. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980;79:1199-204.
2. Greenberg GR, Fleming CR, Jeejeebhoy KN, Rosenberg IH, Sales D, Tremaine WJ. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 1988;29:1309-15.
3. Lochs H, Steinhardt HJ, Klaus-Wentz B, Zeitz M, Vogelsang H, Sommer H, et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease: Results of the european cooperative Crohn's disease study. Gastroenterology 1991;101:881-8.
4. Sandborn WJ. Are short-chain fatty acid enemas effective for left-sided ulcerative colitis ? Gastroenterology 1998;114:218-9.
5. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's diseases. N Engl J Med 1994;334:1557-60.
6. Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. Scand J Gastroenterol 1996;31:778-85.
7. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997;8:159-66.
8. Lefebvre M, Paulweber B, Fajas L, Woods J, McCrary C, Colombel JF, et al. Peroxisome proliferator-activated receptor gamma (PPARg) is induced during differentiation of colon epithelium cells. J Endocrinol 1999;162:331-40.
9. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, et al. Attenuation of colon inflammation through activators of the RXR/PPARγ heterodimer: A basis for new therapeutic strategies. J Exp Med 2001;193:827-38.
10. Desreumaux P. Rôle de la flore dans les maladies inflammatoires chroniques. La Lettre de l'Hépato-gastroentérologue 1999;5:21-5.
11. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4.
12. Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini F, Helwig U, Amadini C, Romboli E, Gionchetti P. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology 2000;118:4179.
13. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.
14. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999;354:635-9.
15. Gionchetti et al referenced 11 in the previous version.